
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia Corp has demonstrated a strong financial outlook supported by an increase in sales estimates for its product YUTREPIA, now projected to reach peak sales of $1.7 billion to $2 billion, significantly higher than prior expectations. The company achieved operating profitability in the first full quarter following YUTREPIA's launch, aided by impressive patient outcomes, particularly a notable increase in 6-Minute Walk Distance (6MWD) metrics. Additionally, favorable Phase 3 data for L606, coupled with strategic advancements in patient transition to YUTREPIA from parenteral therapies, reinforces Liquidia's competitive positioning in the pulmonary hypertension market.
Bears say
Liquidia Corp faces considerable legal risks that could jeopardize its exclusivity and top-line growth from its primary product, YUTREPIA (treprostinil) inhalation powder. Ongoing lawsuits related to UTHR's patents and trade secret misappropriation may impair the company's operational freedom unless favorable judgments are received, which introduces significant downside risk for its stock. Additionally, even if Liquidia successfully appeals the '327 patent lawsuit, the potential for disruptions in sales and overall sales continuity raises concerns about the company's growth potential in the competitive pulmonary hypertension market.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares